<DOC>
	<DOCNO>NCT00121849</DOCNO>
	<brief_summary>This study evaluate safety Leish-111f + MPL-SE vaccine adult subject previous exposure Leishmania parasite ( without current past history leishmaniasis ) .</brief_summary>
	<brief_title>Safety Study Evaluate Leish-111f + MPL-SE Vaccine Prevention Cutaneous Leishmaniasis Healthy Subjects Previously Exposed Leishmania Parasite</brief_title>
	<detailed_description>Cutaneous leishmaniasis disfigure disease progress mucosal leishmaniasis , serious possibly fatal form Leishmania disease . All available medical therapy require week treatment cause significant toxicity . It appear Leishmania infection eliminate prevented T helper 1 immune response . These finding argue vaccine generates T helper 1 response parasite prevent infection disease . This phase 1 , open-label study evaluate safety , tolerability immunogenicity Montenegro skin test ( MST ) -positive healthy adult investigational vaccine develop prophylaxis cutaneous leishmaniasis . The vaccine , identify Leish-111f + MPL-SE , consist recombinant three-antigen Leishmania polyprotein ( Leish-111f , 10 μg ) together adjuvant MPL-SE ( 25 μg ) . The vaccine give study subject three time 4 week interval .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Must positive Montenegro skin test ( reaction &gt; 5 mm ) Must good general health normal lab value Negative HIV , hepatitis B C History leishmaniasis exposure Leishmania vaccine MPLSE . Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Leishmaniasis ,</keyword>
	<keyword>Subunit Vaccine ,</keyword>
	<keyword>Prevention ,</keyword>
	<keyword>T cell</keyword>
</DOC>